 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || m-ceNK cells / ImmunityBio
Enrollment closed: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 9, 2025
P1, N=50, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Recruiting --> Active, not recruiting
- | m-ceNK cells / ImmunityBio, ETBX-071 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date: Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. (clinicaltrials.gov) - May 6, 2025
P2, N=20, Not yet recruiting, Sponsor: ImmunityBio, Inc.
Recruiting --> Active, not recruiting Initiation date: Jan 2025 --> Jun 2025
- | m-ceNK cells / ImmunityBio, ETBX-071 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date: Immunotherapy Before and After Surgery (clinicaltrials.gov) - May 5, 2025
P2, N=20, Not yet recruiting, Sponsor: ImmunityBio, Inc.
Initiation date: Jan 2025 --> Jun 2025 Initiation date: Jan 2025 --> May 2025
- m-ceNK cells / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
QUILT 3.076 phase 1 study of memory-like cytokine-enriched natural killer (M-CENK) cells plus N-803 in locally advanced or metastatic solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 321a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_812;
P1
Preliminary efficacy objectives in cohort 2B are objective response rate (RECIST v1.1 and iRECIST criteria) and progression-free and overall survival evaluated using Kaplan-Meier methods. As of January 27, 2025, 15 participants have been enrolled in cohort 1, 21 participants in cohort 2 have undergone apheresis, and 10 participants have been treated with study therapies.
- | m-ceNK cells / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date: A Phase 2, Open-label, Single-arm Study of Autologous M-CENK Adoptive Cell Therapy and N-803 (IL-15 Superagonist) in Combination with Gemcitabine in Participants with Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov) - Feb 13, 2025
P2, N=20, Recruiting, Sponsor: ImmunityBio, Inc.
As of January 27, 2025, 15 participants have been enrolled in cohort 1, 21 participants in cohort 2 have undergone apheresis, and 10 participants have been treated with study therapies. Initiation date: Dec 2024 --> Mar 2025
- || m-ceNK cells / ImmunityBio, ETBX-071 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P2 trial: Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. (clinicaltrials.gov) - Jan 9, 2025
P2, N=20, Not yet recruiting, Sponsor: ImmunityBio, Inc.
- || m-ceNK cells / ImmunityBio, ETBX-071 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P2 trial: Immunotherapy Before and After Surgery (clinicaltrials.gov) - Jan 9, 2025
P2, N=20, Not yet recruiting, Sponsor: ImmunityBio, Inc.
- || m-ceNK cells / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open: A Phase 2, Open-label, Single-arm Study of Autologous M-CENK Adoptive Cell Therapy and N-803 (IL-15 Superagonist) in Combination with Gemcitabine in Participants with Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov) - Dec 4, 2024
P2, N=20, Recruiting, Sponsor: ImmunityBio, Inc.
Initiation date: Dec 2024 --> Mar 2025 Not yet recruiting --> Recruiting
- || m-ceNK cells / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P2 trial: A Phase 2, Open-label, Single-arm Study of Autologous M-CENK Adoptive Cell Therapy and N-803 (IL-15 Superagonist) in Combination with Gemcitabine in Participants with Recurrent Platinum-Resistant High-Grade Ovarian Cancer (clinicaltrials.gov) - Nov 29, 2024
P2, N=20, Not yet recruiting, Sponsor: ImmunityBio, Inc.
- | m-ceNK cells / ImmunityBio
Trial completion date, Trial primary completion date: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 18, 2024
P1, N=50, Recruiting, Sponsor: ImmunityBio, Inc.
Not yet recruiting --> Recruiting Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
- || m-ceNK cells / ImmunityBio
Enrollment change, Trial completion date, Trial primary completion date: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 18, 2023
P1, N=50, Recruiting, Sponsor: ImmunityBio, Inc.
Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025 N=30 --> 50 | Trial completion date: Jun 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
- || m-ceNK cells / ImmunityBio
Enrollment open: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 26, 2021
P1, N=30, Recruiting, Sponsor: ImmunityBio, Inc.
N=30 --> 50 | Trial completion date: Jun 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Jun 2024 Not yet recruiting --> Recruiting
- || m-ceNK cells / ImmunityBio
New P1 trial: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 24, 2021
P1, N=30, Not yet recruiting, Sponsor: ImmunityBio, Inc.